A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2303 in Healthy Adult

Clinical trial NCT07199270 · RECRUITING

Trial details

NCT number: NCT07199270
Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Health Adult Subjects

Start date: 2025-09-18
Primary completion: 2026-09-18
Enrollment: 64

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.